<DOC>
	<DOCNO>NCT00206167</DOCNO>
	<brief_summary>The purpose study compare Symbicort pressurize metered-dose inhaler ( pMDI ) formoterol placebo long-term maintenance treatment patient chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>A Comparison Symbicort® pMDI 2 x 160/4.5 μg Bid 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid Placebo Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>A clinical diagnosis COPD symptoms 2 year . Smoking history 10 pack year A history least one COPD exacerbation require course oral steroid and/or antibiotic within 112 month first visit . A history asthma Patients take oral steroid Any significant disease disorder may jeopardize safety patient</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>